Impax Reports Third Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street set for lower open as Iran tensions jolt sentiment; chip stocks fall
- SK Hynix’s record plunge drags down global chip stocks
- Oil gains over 3% as fresh military strikes threaten Hormuz shipments
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Impax Laboratories (IPXL) PT Lowered to $16 at Cowen
November 10, 2017 8:15 AM ESTCowen lowered its price target on Impax Laboratories (NASDAQ: IPXL) to $16.00 (from $17.00) while maintaining a Market Perform rating. The Concerta delay and Renvela update were disappointing, but management is able to accelerate the previously announced cost reductions to partially offset this lack of... More
Impax Laboratories (IPXL) Tops Q3 EPS by 3c
November 9, 2017 7:05 AM ESTImpax Laboratories (NASDAQ: IPXL) reported Q3 EPS of $0.23, $0.03 better than the analyst estimate of $0.20. Revenue for the quarter came in at $206.4 million versus the consensus estimate of $208.36 million.
For earnings history and earnings-related data on Impax Laboratories (IPXL) click here.
... More